KPV

animalThe enhanced therapeutic effect of the KPV/SH-PGA hydrogel on colitis was confirmed on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced ulcerative colitis rats⁷

animalColitis symptoms including body weight loss and the disease activity index score were obviously attenuated by rectally administering the KPV/SH-PGA hydrogel⁷

animalThe KPV/SH-PGA hydrogel prevented the colon shortening of TNBS-infused rats and decreased the colonic myeloperoxidase level⁷

animalThe morphology of the colon including the epithelial barrier, crypt, and intact goblet cells was recovered after KPV/SH-PGA hydrogel treatment⁷

animalIn vivo α-MSH has been shown to be anti-inflammatory in animal models of fever, irritant and allergic contact dermatitis, cutaneous vasculitis, fibrosis, in ocular, gastrointestinal, brain and allergic airway inflammation and arthritis⁹

animalOral administration of KPV reduces the incidence of DSS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression¹⁰

animalOral administration of KPV reduces the incidence of TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression¹⁰

animalKPV (alpha-MSH 11-13) resulted in significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity in a model of crystal-induced peritonitis in mice¹²

animalKPV exhibited anti-inflammatory effect in IL-1beta-induced peritonitis inflammation in mice¹²

animalKPV exhibited anti-inflammatory effect in mice with nonfunctional MC1-R (recessive yellow e/e mice)¹²

animalSystemic and topical application of KPV inhibited the sensitization and elicitation phase of contact hypersensitivity (CHS) in a mouse model¹³

animalKPV was able to induce hapten-specific tolerance in a mouse model of contact hypersensitivity¹³

animalalpha-MSH administered systemically during reperfusion reduced ischemia/reperfusion deficits in dogs¹⁶

animalalpha-MSH was more effective when given during both ischemia and reperfusion compared to reperfusion alone in dogs¹⁶

animalKPV demonstrated significant anti-inflammatory activity at doses ranging from 100-1000 mcg/kg in murine models, with optimal efficacy observed at 500-750 mcg/kg daily administration¹⁷

animalPreclinical research has identified KPV as a powerful inhibitor of NF-kB signaling with demonstrated efficacy in animal models of inflammatory bowel disease, contact dermatitis, and bronchial inflammation²⁰

animalIn mouse models of colitis, oral KPV reduced the severity of disease triggered by both DSS and TNBS²¹

animalKPV showed earlier recovery, better weight regain, and fewer inflammatory infiltrates in two different colitis models²¹

animalAnimal model studies have shown that KPV may reduce intestinal permeability and support mucosal healing²³

animalMost research on KPV has been conducted in labs and on mice²⁵

animalAnimal studies have found that KPV may help reduce the severity of ulcerative colitis²⁶

animalIn mouse colitis models, KPV reduced disease severity²⁹

animalDalmasso et al. (2008) showed oral KPV reduced severity of two different types of induced colitis in mice²⁹

animalDalmasso et al. 2008 established KPV as a PepT1-mediated anti-inflammatory tripeptide in two mouse colitis models (DSS-induced and TNBS-induced)³⁰

animalKannengiesser et al. 2008 replicated the effect in additional IBD models from a separate research group³⁰

in vitroKPV showed inhibitory influences against the gram-positive bacterium Staphylococcus aureus²

in vitroKPV showed inhibitory influences against the yeast Candida albicans²

in vitroTreatment with 50 μg/mL of KPV restored cell viability⁴

in vitroIn a three-dimensional (3D) skin model, KPV treatment effectively attenuated the inflammatory cell death induced by PM⁴

in vitroalpha-MSH peptides significantly inhibited S. aureus colony formation¹⁴

in vitroSmall concentrations of alpha-MSH peptides reduced viability and germ tube formation of C. albicans¹⁴

in vitroIn murine microglia cells, alpha-MSH reduced TNF-alpha and nitric oxide production in response to challenge¹⁶

in vitroIn human astrocytes, both alpha-MSH (1-13) and alpha-MSH (11-13) reduced TNF-alpha¹⁶

in vitroA 2007 study found that KPV could be a therapeutic agent for inflammatory bowel disease²⁵

in vitroCell research suggests that the peptide could support skin healing²⁶

expert opinionKPV has potential benefits for inflammation, immune function, and wound healing¹⁹

expert opinionResearchers including Anna Catania and James Lipton at Weill Cornell Medical College conducted systematic studies demonstrating that alpha-MSH could reduce fever, suppress inflammatory responses, and modulate immune cell activity beginning in the 1980s²⁰

expert opinionThe evidence base is primarily preclinical²³

expert opinionHuman clinical trial data for KPV is very limited²³

expert opinionKPV is investigational, most of what is known comes from cell-culture and animal research, and human clinical data are limited²⁴

expert opinionKPV has been studied in human cell systems and animal models, especially around intestinal inflammation, NF-kB signaling, peptide transport, and alpha-MSH-related immunomodulatory pathways²⁷

expert opinionZero human clinical trials exist for KPV²⁹

expert opinionAs of April 2026, KPV has no published Phase 2 or Phase 3 human clinical trial for any indication³⁰

expert opinionKPV retains the parent hormone's potent anti-inflammatory activity without causing skin tanning or sexual side effects³¹

anecdotalMany patients report improved subjective sleep quality, particularly where sleep disruption is inflammation-mediated¹⁸

anecdotalsermorelin meaningfully improved my sleep²²

human studyalpha-MSH is present in barrier organs such as gut and skin²

human studyPepT1 (oligopeptide transporter) is overexpressed in colonic epithelial cells of chronic ulcerative colitis⁸

human studyKPV triggers intracellular calcium responses in human keratinocytes, suggesting it has direct effects on skin cells independent of the traditional cyclic AMP pathway²²

animalNLRP3 expression is significantly upregulated in the melanocytes of vitiligo patients and melanoma-Treg-induced vitiligo mouse model³

animalDownregulation of the E3 ligase β-TrCP1 in vitiligo melanocytes decreases K27-linked ubiquitination levels of NLRP3³

animalDecreased K27-linked ubiquitination of NLRP3 weakens its interaction with the autophagy receptor NDP52³

animalImpaired autophagic degradation of NLRP3 leads to hyperactivation of inflammation and pyroptosis in melanocytes³

animalKPV mice (vimentin knockout crossed with LSL-Kras; Tp53 mice) have attenuated tumor growth and improved survival compared with KPV mice⁵

animalWithaferin A (WFA) suppresses tumor growth and reduces tumor burden in the lung in KPV mice⁵

animalKPV and KPV cells fail to metastasize, suggesting that cell-autonomous metastasis requires mature vimentin intermediate filaments⁵

animalKPV cells upregulate genes associated with ferroptosis, an iron-dependent form of regulated cell death⁵

animalKPV cells have reduced glutathione peroxidase 4 (GPX4) levels, resulting in the accumulation of toxic lipid peroxides and increased ferroptosis⁵

animalVimentin is required for rapid tumor growth, metastasis, and protection from ferroptosis in NSCLC⁵

animalThe epithelial barrier of the colon effectively recovered following PMSP-KPV treatment⁶

animalPMSP-KPV modulated the gut flora, markedly augmenting the abundance of beneficial microorganisms in gut homeostasis⁶

animalThe mechanism by which PMSP-KPV induces a therapeutic effect may be associated with the inhibition of oxidative stress⁶

animalThe KPV/SH-PGA hydrogel decreased the expression of proinflammatory cytokines such as tumor necrosis factor α and interleukin 6⁷

animalKPV is a tripeptide (Lys-Pro-Val) which possesses anti-inflammatory properties¹⁰

animalPepT1 is a di/tripeptide transporter normally expressed in the small intestine and induced in colon during inflammatory bowel disease (IBD)¹⁰

animalKPV is transported into cells by PepT1¹⁰

animalThe antimigratory effect of KPV was not blocked by the MC3/4-R antagonist SHU9119¹²

animalKPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions¹²

animalKPV (alpha-MSH 11-13, the C-terminal tripeptide of alpha-MSH) is able to bind to MC-1R and modulate the function of APCs¹³

animalTolerance induction by KPV is mediated by the generation of CTLA4(+) and IL-10-producing T lymphocytes¹³

animalalpha-MSH modulates peripheral inflammation by acting on melanocortin receptors in host cells (macrophages, neutrophils) to inhibit production of proinflammatory agents¹⁶

animalalpha-MSH acts directly within the brain to modulate local inflammation¹⁶

animalIn dogs, ischemia/reperfusion in the posterior circulation causes inflammatory reactions and disturbance of function (decreases in auditory-evoked potentials)¹⁶

animalKPV reduced inflammatory markers in DSS- and TNBS-induced mouse colitis models²⁷

animalMurine inflammatory bowel disease study reported anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models²⁷

animalAnimal studies suggest KPV promotes mucosal barrier repair and restoration in inflamed colon tissue²⁸

animalKPV's anti-inflammatory effect is mediated through PepT1 (intestinal peptide transporter) and downstream NF-κB pathway inhibition³⁰

in vitroKPV is an endogenous peptide derived from α-melanocyte-stimulating hormone⁴

in vitroPM markedly suppresses HaCaT cell proliferation via cytotoxic effects⁴

in vitroPM induces a pro-inflammatory response by increasing IL-1β secretion⁴

in vitroKPV reduced IL-1β secretion disrupted by PM exposure⁴

in vitroKPV inhibited reactive oxygen species (ROS) production⁴

in vitroKPV decreased the expression of apoptosis-related proteins (Bax, Bcl-2, and cleaved caspase-3)⁴

in vitroKPV suppressed the redox-sensitive transcription factor nuclear factor-kappa B in PM-treated HaCaT cells⁴

in vitroKPV blocked ROS-mediated caspase-1 activation, reducing IL-1β secretion⁴

in vitroKPV protects keratinocytes by mitigating PM-induced pyroptosis⁴

in vitroKPV (Lys-Pro-Val) is the C-terminal sequence of α-MSH⁸

in vitroKPV can be delivered by PepT1 into cytosol in the intestine⁸

in vitroDCM-KPV accumulates in cytoplasm and nucleus of Caco-2 cells overexpressing PepT1⁸

in vitroα-Melanocyte-stimulating hormone (α-MSH) is a potent anti-inflammatory mediator⁹

in vitroα-MSH affects various pathways regulating inflammatory responses such as NF-κB activation, expression of adhesion molecules, inflammatory cytokines, chemokine receptors, T-cell proliferation and activity and inflammatory cell migration⁹

in vitroKPV retains almost all of the anti-inflammatory capacity of the full hormone α-MSH⁹

in vitroSignificant similarities between anti-inflammatory signaling of α-MSH and KPV short peptides exist⁹

in vitroNanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways¹⁰

in vitroKPV reduces pro-inflammatory cytokine secretion in human intestinal epithelial cells and human T cells¹⁰

in vitroKPV acts via PepT1 expressed in immune and intestinal epithelial cells¹⁰

in vitroKPV is a carboxyl terminal tripeptide of alpha-MSH and represents one of the smallest minimal sequences reported to prevent inflammation¹¹

in vitroNo elevation in cyclic AMP was detected in HaCaT or normal human keratinocytes in response to KPV peptides¹¹

in vitroRapid and acute intracellular calcium elevation was observed in HaCaT keratinocytes in response to KPV in the presence of PIA, an adenosine agonist¹¹

in vitroNormal keratinocytes responded to KPV peptides with intracellular calcium elevation¹¹

in vitroStable transfection of Chinese hamster ovary cells with the MC-1 receptor showed that KPV peptides elevated intracellular calcium¹¹

in vitroIn vitro, macrophage activation (determined as release of KC and IL-1beta) was not inhibited by KPV, unlike alpha-MSH and MTII¹²

in vitroKPV failed to increase cAMP accumulation, unlike MTII¹²

in vitroKPV modulates IgE production by IL-4 and anti-CD40 stimulated B lymphocytes in vitro¹³

in vitroKPV (carboxy-terminal tripeptide 11-13 of alpha-MSH) has antimicrobial influences against Staphylococcus aureus¹⁴

in vitroKPV has antimicrobial influences against Candida albicans¹⁴

in vitroalpha-MSH peptides reversed the enhancing effect of urokinase on S. aureus colony formation¹⁴

in vitroAntimicrobial influences of alpha-MSH peptides could be mediated by their capacity to increase cellular cAMP¹⁴

in vitroDideoxyadenosine (ddAdo), a potent adenylyl cyclase inhibitor, partly reversed the killing activity of alpha-MSH peptides¹⁴

in vitroalpha-MSH peptides enhanced killing of C. albicans and S. aureus by human neutrophils without reducing killing¹⁴

in vitroKPV is a fragment of alpha-MSH that modulates inflammation via three general actions: direct actions on peripheral host cells; actions on inflammatory cells within the brain to modulate local reactions; and descending neural anti-inflammatory pathways that control inflammation in peripheral tissues¹⁵

in vitroAlpha-MSH inhibits activation of NF-kappa B nuclear factor through preservation of I kappa B alpha, which binds to NF-kappa B and prevents its migration to the nucleus¹⁵

in vitroCells transfected with alpha-MSH plasmid vector are resistant to challenge with bacterial lipopolysaccharide¹⁵

in vitroAlpha-MSH modulates the production and action of proinflammatory cytokines in inflammatory cells in the periphery and within the central nervous system¹⁵

in vitroIn human bronchial epithelial cells, alpha-MSH C-terminal peptides translocate into the cell nucleus and competitively block the interaction between importin-alpha3 (Imp-alpha3) and the p65/RelA subunit of NF-kB²⁰

in vitroα-MSH and its C-terminal KPV sequence inhibit the growth of pathogens including Staphylococcus aureus and the yeast Candida albicans²¹

in vitroIn intestinal cells, nanomolar amounts of KPV blocked NF-κB activation and a second pathway called MAP kinase, which dropped the output of pro-inflammatory cytokines²¹

in vitroalpha-MSH peptides including KPV inhibited Staphylococcus aureus and Candida albicans at physiological concentrations, and importantly did not reduce the killing capacity of human neutrophils²²

in vitroKPV entered intestinal epithelial and immune-cell models through hPepT1 and reduced inflammatory signaling outputs²⁷

in vitroKPV inhibited NF-kB and MAP kinase inflammatory signaling in cell models²⁷

in vitroKPV has been studied in human bronchial epithelial cells, where researchers reported suppression of TNF-alpha-evoked NF-kB activity, IL-8 release, and MMP-9 activity²⁷

in vitroKPV mitigates fine particulate matter (PM10)-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB signaling pathway²⁸

in vitroTripeptides including KPV regulate cell migration, proliferation, and differentiation while modulating inflammation in the wound-healing context²⁸

in vitroKPV and rapamycin (RAPA) can self-assemble into carrier-free nanodrugs, with preliminary preclinical data suggesting potential utility in vascular calcification models²⁸

in vitroKPV enters inflamed gut cells through PepT1, a transporter upregulated in inflamed tissue²⁹

in vitroKPV inhibits NF-kB at nanomolar concentrations²⁹

in vitroKPV suppresses TNF-alpha, IL-1beta, and IL-6²⁹

in vitroKPV does not bind melanocortin receptors²⁹

expert opinionKPV is an α-melanocyte stimulating hormone-derived tripeptide¹

expert opinionThe mechanism linking KPV's anti-inflammatory profile to sleep benefits is consistent with the broader biology of inflammation-mediated sleep disruption¹⁸

expert opinionKPV is a tripeptide (Lys-Pro-Val) derived from alpha-MSH with potent anti-inflammatory properties²⁰

expert opinionKPV works primarily by inhibiting NF-kB signaling, a master regulator of inflammation²⁰

expert opinionKPV retains the potent anti-inflammatory activity of its parent hormone while lacking alpha-MSH's pigmentation effects²⁰

expert opinionKPV does not bind to melanocortin receptors and does not increase intracellular cAMP²⁰

expert opinionKPV suppresses pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)²⁰

expert opinionKPV exhibits antimicrobial activity against Staphylococcus aureus and Candida albicans²⁰

expert opinionThe specific importin-alpha3 mechanism has not been directly demonstrated for KPV itself in a primary peer-reviewed study; it is extrapolated from related alpha-MSH fragment research²⁰

expert opinionKPV stabilizes IkB-alpha (the cytoplasmic inhibitor of NF-kB) and suppresses the nuclear translocation of p65²⁰

expert opinionKPV peptide is a tripeptide made of lysine, proline, and valine that comes from the tail end of alpha-melanocyte-stimulating hormone (α-MSH)²¹

expert opinionKPV is studied as an anti-inflammatory and antimicrobial agent that calms overactive immune signaling without shutting the immune system down²¹

expert opinionKPV is the last three amino acids of α-MSH, the sequence at positions 11 to 13, written as Lys-Pro-Val²¹

expert opinionA three-amino-acid chain can ride into cells through the PepT1 transporter, a protein that normally shuttles small dietary peptides across the gut wall²¹

expert opinionKPV tones down excess signaling rather than disabling the immune response, so the body's normal defenses are meant to stay intact²¹

expert opinionKPV is a tripeptide (three amino acids: lysine, proline, valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH)²²

expert opinionKPV has centered on its ability to reduce inflammation through the NF-kB pathway²²

expert opinionKPV inhibits NF-kB activation, which reduces the downstream cascade of inflammatory signaling²²

expert opinionKPV also signals through melanocortin receptors and calcium signaling pathways²²

expert opinionKPV has demonstrated antimicrobial properties²²

expert opinionPepT1 ferries KPV into intestinal and immune cells where it shuts down NF-kB and MAP kinase signaling²²

expert opinionAt only three amino acids, it is one of the smallest peptides with demonstrated biological activity²²

expert opinionKPV is a naturally derived tripeptide fragment of alpha-MSH²³

expert opinionKPV stands for lysine-proline-valine, the three amino acids that form this short peptide chain²³

expert opinionKPV is derived from the C-terminus of alpha-melanocyte-stimulating hormone, a naturally occurring hormone involved in immune regulation and inflammation control²³

expert opinionKPV binds to melanocortin receptors, particularly MC1R and MC3R, which are expressed in immune cells and in the epithelial lining of the gut²³

expert opinionBy engaging these receptors, KPV may downregulate pro-inflammatory signaling molecules including TNF-alpha, IL-6, and IL-1beta²³

expert opinionAlpha-MSH is produced in the pituitary and helps regulate immune function, fever, and inflammation through the melanocortin receptor system²⁴

expert opinionThis small fragment appears to retain meaningful anti-inflammatory activity while shedding the pigmentation effects associated with the full alpha-MSH molecule²⁴

expert opinionKPV is a peptide made of three amino acids—lysine (K), proline (P), and valine (V)²⁵

expert opinionKPV is created from a fragment of the α‑MSH hormone, which helps control inflammation²⁶

expert opinionKPV is a three-amino-acid peptide with the sequence lysine-proline-valine²⁷

expert opinionKPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone, usually written as alpha-MSH(11-13)²⁷

expert opinionKPV is a tripeptide (Lys-Pro-Val) derived from the tail end of alpha-MSH²⁹

expert opinionKPV retains alpha-MSH's anti-inflammatory activity without tanning effects because tanning requires a different part of the molecule²⁹

expert opinionKPV is a tripeptide (Lys-Pro-Val) consisting of the C-terminal 11-13 residues of α-MSH³⁰

expert opinionKPV retains the anti-inflammatory activity of α-MSH while not requiring melanocortin receptor engagement³⁰

expert opinionKPV does not produce melanocortin-receptor-mediated effects of α-MSH including no pigmentation, sexual effects, appetite suppression, or BP elevation³⁰

expert opinionKPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-MSH³¹

expert opinionKPV achieves anti-inflammatory effects through a receptor-independent mechanism — directly inhibiting the NF-kB inflammatory signaling pathway³¹

expert opinionKPV blocks the IKK complex from phosphorylating IkBa, which prevents NF-kB from entering the nucleus and activating inflammatory gene transcription³¹

expert opinionKPV effectively shuts down production of TNF-alpha, IL-1beta, IL-6, COX-2, and other inflammatory mediators³¹

theoreticalKPV is a fragment of alpha-melanocyte-stimulating hormone (alpha-MSH)²

theoreticalKPV (Lys-Pro-Val) is a tripeptide derived from α-MSH (α-melanocyte-stimulating hormone)⁷

theoreticalKPV, C-terminal tripeptide of α-MSH, lacks the entire sequence motif required for binding to any of the known MC-Rs⁹

theoreticalIt is not known if KPV operates via MC-1R or cyclic AMP for its anti-inflammatory properties¹¹

theoreticalKPV (Ac-KPV-NH2) is a synthetic tripeptide consisting of lysine-proline-valine amino acid sequence, derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH)¹⁷

theoreticalKPV exerts its primary effects through melanocortin receptor activation, particularly MC1R and MC3R subtypes, which regulate inflammatory cascades and epithelial barrier function¹⁷

theoreticalThe peptide's mechanism of action involves modulation of nuclear factor kappa B (NF-κB) signaling pathways, reducing pro-inflammatory cytokine production including tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β)¹⁷

theoreticalKPV is a short, lab-synthesized chain of just three amino acids: lysine, proline, and valine²⁴

theoreticalKPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) — specifically the residues at positions 11 through 13 of that thirteen-amino-acid neuropeptide²⁴

theoreticalKPV (lysine-proline-valine) is a tripeptide derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH)²⁸

theoreticalKPV is classified among host defense peptides with combined antimicrobial and immunomodulatory properties relevant to inflammatory bowel disease²⁸

expert opinionSubcutaneous injection in low-microgram to low-milligram range per dose, often with cycling between active and off periods¹⁸

expert opinionTopical formulations use low-percentage concentrations in appropriate vehicle¹⁸

expert opinionKPV is often used in cycling rather than continuous use¹⁸

expert opinionKPV is typically administered as a pill, injection, or topical cream²⁶

expert opinionNo human protocol data exist to guide monitoring, dose adjustment, or duration of use²⁸

expert opinionStandard dosing is 200-500 mcg subcutaneous daily or oral for gut applications, typically cycled 4-8 weeks³¹

anecdotalKPV is available as oral capsules from supplement vendors despite complete absence of human data²⁹

theoreticalTopical formulations have been investigated for localized anti-inflammatory effects, though systemic bioavailability remains limited at 15-25% compared to injectable forms¹⁷

in vitroThe KPV/SH-PGA hydrogel presented a shear-thinning behavior, which was helpful for rectal administration⁷

in vitroOnly 30% of KPV was released from the KPV/SH-PGA hydrogel within 20 min, followed by a sustained-release behavior⁷

in vitroThe stability of KPV in the SH-PGA hydrogel was obviously enhanced, which was presented by detecting its anti-inflammatory activity and promoting cell migration potential after 2 h of exposure to 37 °C⁷

expert opinionKPV is a three-amino-acid peptide with a short in vivo half-life¹⁸

expert opinionPublished pharmacokinetic data are limited compared to larger peptides¹⁸

expert opinionKPV can be actively transported across cell membranes by the PepT1 di/tripeptide transporter²⁰

expert opinionThis mechanism operates at nanomolar concentrations²⁰

expert opinionKPV is small enough to survive the digestive tract and get absorbed intact, so it can be taken by mouth²¹

expert opinionKPV is carried into cells by a transporter called PepT1, which normally lives in the small intestine but becomes much more active in the colon during inflammation²²

expert opinionNo pharmacokinetics data exists in any species for KPV²⁹

expert opinionKPV has oral bioavailability due to its small size (only 3 amino acids) and resistance to gastrointestinal proteases³¹

theoreticalHalf-life: Approximately 2-4 hours in plasma, requiring daily administration for sustained effects¹⁷

theoreticalBioavailability: Subcutaneous administration achieves 85-95% bioavailability compared to intravenous delivery¹⁷

theoreticalMolecular weight is 357.46 Da, making it highly bioavailable through subcutaneous administration routes¹⁷

theoreticalKPV achieves peak plasma concentrations within 30-60 minutes following subcutaneous injection, with bioavailability ranging from 85-95% compared to intravenous administration¹⁷

theoreticalThe peptide undergoes rapid enzymatic degradation by peptidases, contributing to its short duration of action and requiring consistent daily dosing schedules¹⁷

theoreticalIntramuscular injection may provide slightly higher bioavailability at 90-98%, though absorption kinetics are slower with peak concentrations occurring 60-90 minutes post-injection¹⁷

theoreticalIntranasal administration achieves 40-60% bioavailability but requires twice-daily dosing due to rapid mucosal clearance¹⁷

expert opinionKPV is not an FDA-approved consumer medicine²⁷

expert opinionNo FDA, EMA, or Health Canada approval or authorization exists for KPV as a standalone therapeutic²⁸

expert opinionThe safety assumption for KPV rests on it being a fragment of an endogenous hormone and a simple tripeptide of three natural amino acids with no modifications²⁹

expert opinionFDA is evaluating KPV for wound healing and inflammatory conditions via Pharmacy Compounding Advisory Committee for Section 503A Bulk Drug Substances List as of July 23, 2026³⁰

expert opinionCommon side effects include injection site irritation and mild flushing³¹

expert opinionThere is limited human safety data³¹

expert opinionRare risks include allergic reactions and theoretical risk of weakening the immune system with long-term high doses³¹

anecdotalEssentially no side effects reported with KPV at standard doses²⁹

anecdotalOne documented safety incident involved a user injecting VIP instead of KPV due to similar labelling, causing severe flushing, heart racing, and difficulty breathing²⁹

expert opinionKPV can be administered orally²⁰

expert opinionThe clearest research focus for KPV is inflammatory bowel disease, including both ulcerative colitis and Crohn's disease²³

expert opinionResearchers are exploring KPV in wound healing and skin inflammation contexts²³

expert opinionThere is emerging interest in its possible role in metabolic inflammation and neuroinflammation²³

expert opinionCompounded KPV is currently available through some pharmacies and research suppliers²³

expert opinionKPV is a small tripeptide attracting outsized attention for its anti-inflammatory reputation²⁴

expert opinionKPV is a three-amino-acid peptide that has drawn growing interest among clinicians and patients for its reputation as an anti-inflammatory compound, particularly for the gut and skin²⁴

expert opinionFDA has been evaluating KPV for wound healing and treating inflammatory conditions such as colitis²⁵

expert opinionKPV is being evaluated for wound healing and inflammatory conditions²⁶

expert opinionPublic claims around gut repair, autoimmune support, skin healing, and broad anti-inflammatory use run ahead of direct human clinical evidence for KPV drug products²⁷

expert opinionKPV may help with inflammatory skin conditions through targeted anti-inflammatory action³¹

expert opinionKPV is particularly promising for IBD and reaches intestinal epithelium when taken orally³¹

anecdotalover a year of daily OS-01 peptide use through OneSkin²²

anecdotalKPV is currently used in recreational and sport/bodybuilding communities despite an absence of human safety or efficacy data²⁸

anecdotalCommunity uses KPV primarily for gut healing including IBS and colitis²⁹

anecdotalKPV is used as a safe alternative to BPC-157 for people with mast cell activation syndrome, as BPC-157 triggers mast cell flares in this population²⁹

anecdotalKPV has become one of the most-used anti-inflammatory peptides in the community, particularly for IBD-spectrum gut conditions and chronic skin inflammation³⁰

anecdotalKPV is often stacked with BPC-157 in community use³⁰

theoreticalKPV holds potential as a therapeutic agent for preventing environmental pollutant-related skin damage⁴

theoreticalTherapeutic application of KPV as well as KPV-pulsed dendritic cells may be useful for treatment of inflammatory, autoimmune, and allergic diseases¹³

theoreticalKPV is studied preclinically for its anti-inflammatory, mucosal-repair, and wound-healing properties²⁸